Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says
Executive Summary
Wyeth expects to have about one year to switch Effexor XR patients to its follow-on serotonin and norepinephrine reuptake inhibitor DVS-233 before venlafaxine XR loses market exclusivity in 2008